Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
about
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Progress on antiangiogenic therapy for patients with malignant glioma.Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitorsValidating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhUnderstanding drugs in breast cancer through drug sensitivity screeningPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.Canine astrocytic tumors: a comparative review.Role of tyrosine kinase inhibitors in the management of high-grade gliomas.Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines.Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.
P2860
Q27853297-15A5AEE8-9DA2-45FE-AD07-80E46E8048AEQ30388655-B73A6578-CE69-4BCB-991C-BC523C3EF673Q33773189-0D3FC0B4-D525-47F0-928E-34BF23211288Q33863809-900C1764-782D-4780-B2A4-9265DF77CC3EQ35001420-6A4FB836-7C57-46E3-B926-FFFF824D7ABDQ36234079-A325318C-7F93-4295-B060-7D4690762820Q37244802-912112DA-3471-43E4-AB35-0445350C0920Q37808081-31E76FCC-4FC5-430D-993E-5919A0E04EE1Q37952242-FAFF7019-D672-413C-B4BB-E6B175FE9B67Q37992086-2AD88AF0-3068-43D4-8186-1BA004066061Q38552109-3446FB17-E4D5-4FD7-9C6F-92652584CE92Q39965992-04AA6CA6-D425-49F2-BFF2-27D9660A2C96Q41002305-F131CA3B-8580-423F-9D26-C65030B38641
P2860
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@ast
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@en
type
label
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@ast
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@en
prefLabel
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@ast
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@en
P1433
P1476
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
@en
P2093
Jeremy N Rich
Sith Sathornsumetee
P304
P356
10.1358/DOT.2006.42.10.1025318
P577
2006-10-01T00:00:00Z